Q2 FY2026 EarningsQ2 FY26 results beat consensus on earnings but missed on operational cash flow, with revenue remaining at zero as expected for this clinical-stage biotech. Diluted EPS was -$0.36 vs. -$0.79 expected, primarily driven by a $40M milestone gain from the sale of legacy assets. While research and development (R&D) expenses rose 63% YoY to $65.5M, the company maintained a robust cash position of $1.1B, providing over 12 months of runway.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Spyre Therapeutics(SYRE) the EBIT is -41.64 M (+0.71%), Beat estimate;the EPS is -0.36 (+26.53%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITExceed expectations
-0.04B0.71%
-0.08B79.55%
+0.03B80.26%
EPSExceed expectations
-0.3626.53%
-0.785360.26%
+0.425386.79%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf